Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprenetapopt. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprenetapopt SCHEMBL21636035 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL23726645 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL27272034 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965401 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965910 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965601 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965376 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL28990156 | 0.92 | MEN1 (0.60) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL30382084 | 0.91 | MEN1 (0.58) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL23727096 | 0.91 | MEN1 (0.58) | MEN1MAPTCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3849310-B1 | COMBINATION CANCER THERAPIES BASED ON THE MORTALIN TARGETING COMPOUND SHETA2 AND P53 REACTIVATORS OR CDK4/6 INHIBITORS | UNIV OKLAHOMA (US) | 2026-05-13 | — | — | EP | claimed |
| US-12521392-B2 | Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2026-01-13 | — | — | US | claimed |
| US-20260002222-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2026-01-01 | — | — | US | claimed |
| US-20260000740-A1 | USE OF A L-ASPARAGINASE IN COMBINATION WITH A FERROPTOSIS INDUCER FOR THE TREATMENT OF EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA | INST NAT SANTE RECH MED (FR) | 2026-01-01 | — | — | US | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250332150-A1 | METHODS FOR TREATING NOTCH1-DRIVEN CANCERS | INST NAT SANTE RECH MED (FR) | 2025-10-30 | — | — | US | claimed |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | UNIV BROWN (US) | 2025-10-23 | — | — | US | claimed |
| US-12435380-B2 | Compositions and methods for the diagnosis and treatment of ALT cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-10-07 | — | — | US | claimed |
| US-20250302863-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-10-02 | — | — | US | claimed |
| WO-2021053155-A1 | COMBINATION TREATMENT WITH A P53 REACTIVATOR AND AN INHIBITOR OF AN ANTIAPOPTOTIC BCL-2 FAMILY PROTEIN | APREA THERAPEUTICS AB (SE) | 2021-03-25 | — | — | WO | claimed |
| CN-106963759-B | Aqueous solutions comprising 3-quinuclidinone derivatives for the treatment of hyperproliferative diseases, autoimmune diseases and cardiac diseases | 阿普利亚治疗有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-06-15 | — | — | US | claimed |
| EP-3125940-A2 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-02-08 | — | — | EP | claimed |
| EP-2525796-B1 | Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | APREA AB (SE) | 2016-03-30 | — | — | EP | claimed |
| WO-2015150472-A2 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2015-10-08 | — | — | WO | claimed |
| US-9061016-B2 | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | APREA AB (SE) | 2015-06-23 | — | — | US | claimed |
| US-20120289503-A1 | AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE | APREA AB (SE) | 2012-11-15 | — | — | US | claimed |
| WO-2011089234-A2 | METHOD AND COMPOSITION | APREA AB (SE) | 2011-07-28 | — | — | WO | claimed |
| EP-1727817-B1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2010-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | MEN1 2618/4885MAPT 3662/4885CYP2C9 4813/4885 |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | TP53, BRAF, TP53BP1 | MEN1 2962/4885MAPT 3637/4885CYP2C9 4881/4885 |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | DCTD, EZH2, DUT | MEN1 1769/4885MAPT 2747/4885CYP2C9 971/4885 |
| US-20120289503-A1 | AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE | IL17A, JAK1, JAK3 | MEN1 242/4885MAPT 4069/4885CYP2C9 4604/4885 |
| US-20260002222-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | TERT, POT1, TELO2 | MEN1 908/4885MAPT 442/4885CYP2C9 4503/4885 |
| US-20250332150-A1 | METHODS FOR TREATING NOTCH1-DRIVEN CANCERS | TP53, NOTCH1, NOTCH4 | MEN1 1202/4885MAPT 2787/4885CYP2C9 4197/4885 |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | BCOR, CCAR2, CEBPZ | MEN1 3174/4885MAPT 4116/4885CYP2C9 4518/4885 |
| US-20260000740-A1 | USE OF A L-ASPARAGINASE IN COMBINATION WITH A FERROPTOSIS INDUCER FOR THE TREATMENT OF EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA | ERAP1, AIFM2, ERAL1 | MEN1 3842/4885MAPT 4764/4885CYP2C9 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.